When COVID-19 Meets Interstitial Lung Disease: Implications for Acute and Long-Term Management
Patient with ILDs, especially those with a progressive fibrosis phenotype, maybe at a greater risk for having worse outcomes with COVID-19, including during and post-COVID-19 infection. However, the management of patients with PF-ILDs and COVID-19 is not clear, including the potential management of COVID-19 related lung injury and fibrosis, as well as the overall management of ILDs in the COVID-19 era. During this webcast, experts will discuss these gaps and the implications of COVID-19 in the management of patients with ILDs and PF-ILD.
Pulmonologists, Radiologists, Pathologists, Residents and other Allied HCPs who care for patients with ILD.
After completing this activity, the participant should be better able to:
- Discuss the impact of COVID-19 in patients with PF-ILDs
- Interpret the evidence for the management of patients with PF-ILDs who have contracted COVID-19
- Review the long-term management and follow-up of patients with PF-ILDs post-COVID-19
Lisa H. Lancaster, MD
Professor of Medicine
Vanderbilt University Medical Center
Dr. Lancaster discloses the following:
Her spouse earns salary for Medtronic
Consulting Fees: Galapagos, United Therapeutics, AstraZeneca, BMS
Fees for Non-CME/CE Services: Boehringer Ingelheim, Genentech
Contracted Research: Novartis, Celgene, Boehringer Ingelheim, Galapagos, Galactic, BMS, Pliant
Steven Nathan, MD
Medical Director, Advanced Lung Disease & Transplant Program
Inova Fairfax Hospital
Falls Church, VA USA
Professor of Medicine
Virginia Commonwealth University - Inova Fairfax Campus
Dr. Nathan discloses the following:
Consulting Fees: Boehringer-Ingelheim, Roche, United Therapeutics
Fees for Non-CME/CE Services: Bellerophon, Galapagos
Contracted Research: United Therapeutics, Bellerophon
ESTIMATED TIME TO COMPLETE ACTIVITY
EDUCATIONAL GRANT SUPPORT
This activity is supported by an educational grant from Boehringer-Ingelheim.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and TME. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.00 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
This is an knowledge-based activity. Universal Activity Number (UAN): JA4008162-9999-20-2275- H01-P
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The PIM planners and managers have nothing to disclose. The TME planners and managers have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period September 25, 2020 through September 25, 2021, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.pimed.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation